Roles of extracellular chaperones in amyloidosis

Journal of Molecular Biology

Volumn 421, Issue 4-5, 2012, Pages 499-516

  Wyatt, Amy R ^a   Yerbury, Justin J ^a   Dabbs, Rebecca A ^a   Wilson, Mark R ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Alzheimer's disease; clearance; protein aggregation; proteostasis; receptor mediated endocytosis

Indexed keywords

CHAPERONE; SCLEROPROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; BODY FLUID; ENDOCYTOSIS; EXTRACELLULAR SPACE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; REVIEW;

EID: 84863986350     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.01.004     Document Type: Review

References (218)

1. Sitia R., and Braakman I. Quality control in the endoplasmic reticulum protein factory Nature 426 2003 891 894 (Pubitemid 38056881)
2. Bekard I., Asimakis P., Bertolini J., and Dunstan D. The effects of shear flow on protein structure and function Biopolymers 95 2011 733 745
3. Di Stasio E., and De Cristofaro R. The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: the case of von Willebrand factor Biophys. Chem. 153 2010 1 8
4. Hartl F.U., Bracher A., and Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis Nature 475 2011 324 332
5. Gidalevitza T., Kikisa E.A., and Morimoto R.I. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks Curr. Opin. Struct. Biol 20 2010 23 32
6. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., and Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease Microsc. Res. Tech. 50 2000 305 315 (Pubitemid 30651171)
7. Fabrizi C., Businaro R., Lauro G.M., and Fumagalli L. Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? J. Neurochem. 78 2001 406 412 (Pubitemid 32664422)
8. Powers J.M., Schlaepfer W.W., Willingham M.C., and Hall B.J. An immunoperoxidase study of senile cerebral amyloidosis with pathogenetic considerations J. Neuropathol. Exp. Neurol. 40 1981 592 612 (Pubitemid 12248674)
9. Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease Brain Res. 541 1991 163 166
10. Perlmutter L.S., Barron E., Myers M., Saperia D., and Chui H.C. Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions J. Comp. Neurol. 352 1995 92 105
11. Freixes M., Puig B., Rodriguez A., Torrejon-Escribano B., Blanco R., and Ferrer I. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease Acta Neuropathol. 108 2004 295 301 (Pubitemid 39328047)
12. Chiesa R., Angeretti N., Lucca E., Salmona M., Tagliavini F., and Bugiani O. Clusterin (SGP-2) induction in rat astroglial cells exposed to prion protein fragment 106-126 Eur. J. Neurosci. 8 1996 589 597 (Pubitemid 26090764)
13. Adler V., and Kryukov V. Serum macroglobulin induces prion protein transition Neurochem. J. 1 2007 43 52
14. Ishii T., Haga S., Yagishita S., and Tateishi J. The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease Appl. Pathol. 2 1984 370 379 (Pubitemid 16028901)
15. Ghiso J., Plant G.T., Revesz T., Wisniewski T., and Frangione B. Familial cerebral amyloid angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein J. Neurol. Sci. 129 1995 74 75
16. Rostagno A., Lashley T., Ng D., Meyerson J., Braendgaard H., and Plant G. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease J. Neurol. Sci. 257 2007 88 96 (Pubitemid 46863434)
17. Wisniewski T., and Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid Neurosci. Lett. 135 1992 235 238
18. Lashley T., Holton J.L., Verbeek M.M., Rostagno A., Bojsen-Moller M., and David G. Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study Neuropathol. Appl. Neurobiol. 32 2006 492 504 (Pubitemid 44401511)
19. Kida E., Choi-Miura N.H., and Wisniewski K.E. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain Brain Res. 685 1995 211 216
20. Kalaria R.N., and Grahovac I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease Brain Res. 516 1990 349 353 (Pubitemid 20185568)
21. Sakaguchi H., Miyagi M., Shadrach K.G., Rayborn M.E., Crabb J.W., and Hollyfield J.G. Clusterin is present in drusen in age-related macular degeneration Exp. Eye Res. 74 2002 547 549 (Pubitemid 34757032)
22. Chargé S.B., Esiri M.M., Bethune C.A., Hansen B.C., and Clark A. Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease J. Pathol. 179 1996 443 447 (Pubitemid 26276117)
23. Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B.C., and Kuziel W.A. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice Nat. Med. 9 2003 1390 1397 (Pubitemid 37466188)
24. Campistol J.M., Shirahama T., Abraham C.R., Rodgers O.G., Sole M., and Cohen A.S. Demonstration of plasma proteinase inhibitors in B2-microglobulin amyloid deposits Kidney Int. 42 1992 915 923
25. Greene M.J., Sam F., Soo Hoo P.T., Patel R.S., Seldin D.C., and Connors L.H. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy Am. J. Pathol. 178 2011 61 68
26. Magalhaes J., and Saraiva M.J. Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy J. Neuropathol. Exp. Neurol. 70 2011 1097 1106
27. Brambilla F., Lavatelli F., Di Silvestre D., Valentini V., Rossi R., and Palladini G. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue Blood 119 2011 1844 1847
28. Nishida K., Quantock A.J., Dota A., Choi-Miura N.H., and Kinoshita S. Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies Br. J. Ophthalmol. 83 1999 1178 1182 (Pubitemid 29469125)
29. Wilson M.R., and Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone Trends Biochem. Sci. 25 2000 95 98 (Pubitemid 30122416)
30. Humphreys D., Carver J.A., Easterbrook-Smith S.B., and Wilson M.R. Clusterin has chaperone-like activity similar to that of small heat-shock proteins J. Biol. Chem 274 1999 6875 6881
31. Yerbury J.J., Stewart E.M., Wyatt A.R., and Wilson M.R. Quality control of protein folding in extracellular space EMBO Rep. 6 2005 1131 1136 (Pubitemid 41741695)
32. Wyatt A.R., Yerbury J.J., Berghofer P., Greguric I., Katsifis A., and Dobson C.M. Clusterin facilitates in vivo clearance of extracellular misfolded proteins Cell. Mol. Life Sci. 68 2011 3919 3931
33. Bocci V., Masti L., Pacini A., and Viti A. Catabolism of native and denatured serum 131-I-proteins by polymorphonuclear leucocytes Exp. Cell Res. 52 1968 129 139
34. Coffey J.W., and de Duve C. Digestive activity of lysosomes J. Biol. Chem. 243 1968 3255 3263
35. Iwao Y., Anraku M., Yamasaki K., Kragh-Hansen U., Kawai K., and Maruyama T. Oxidation of Arg-410 promotes the elimination of human serum albumin Biochim. Biophys. Acta 1764 2006 743 749
36. Margineanu I., and Ghetie V. A selective model of plasma protein catabolism J. Theor. Biol. 90 1981 101 110 (Pubitemid 11080366)
37. Senior J., Delgado C., Fisher D., Tilcock C., and Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim. Biophys. Acta 1062 1991 77 82
38. Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., and Crowther D.C. ANS binding reveals common features of cytotoxic amyloid species ACS Chem. Biol. 5 2010 735 740
39. Seong S.Y., and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses Nat. Rev., Immunol. 4 2004 469 478 (Pubitemid 38745558)
40. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., and Suuronena T. Inflammation in Alzheimer's disease: amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors Prog. Neurobiol. 87 2009 181 194
41. Herczenik E., Bouma B., Korporaal S.J.A., Strangi R., Zeng Q., and Gros P. Activation of human platelets by misfolded proteins Arterioscler. Thromb. Vasc. Biol. 27 2007 1657 1665 (Pubitemid 46986124)
42. Husemann J., Loike J.D., Anankov R., Febbraio M., and Silverstein S.C. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system Glia 40 2002 195 205 (Pubitemid 35337377)
43. Udan M.L.D., Ajit D., Crouse N.R., and Nichols M.R. Toll-like receptors 2 and 4 mediate Aβ(1-42) activation of the innate immune response in a human monocytic cell line J. Neurochem. 104 2008 524 533 (Pubitemid 350293880)
44. Jana M., Palencia C.A., and Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease J. Immunol. 181 2008 7254 7262
45. Davis G.E. The Mac-1 and p150,95 β2 integrins bind denatured proteins to mediate leukocyte cell-substrate adhesion Exp. Cell Res. 200 1992 242 252
46. Hespanhol M.R., and Mantovani B. Phagocytosis by macrophages mediated by receptors for denatured proteins - dependence on tyrosine protein kinases Braz. J. Med. Biol. Res. 35 2002 383 389 (Pubitemid 34285513)
47. Kranenburg O., Bouma B., Kroon-Batenburg L.M.J., Reijerkerk A., Wu Y.P., and Voest E.E. Tissue-type plasminogen activator is a multiligand cross-β structure receptor Curr. Biol. 12 2002 1833 1839 (Pubitemid 35273903)
48. Bouma B., Kroon-Batenburg L.M., Wu Y.P., Brunjes B., Posthuma G., and Kranenburg O. Glycation induces formation of amyloid cross-beta structure in albumin J. Biol. Chem. 278 2003 41810 41819 (Pubitemid 37310441)
49. Martin-Ventura J.L., Leclercq A., Blanco-Colio L.M., Egido J., Rossignol P., and Meilhac O. Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation Atherosclerosis 194 2007 334 341 (Pubitemid 47513095)
50. Farias M., Gorman M.W., Savage M.V., and Feigl E.O. Plasma ATP during exercise: possible role in regulation of coronary blood flow Am. J. Physiol. Heart Circ. Physiol. 288 2005 H1586 H1590
51. Yerbury J.J., Rybchyn M.S., Easterbrook-Smith S.B., Henriques C., and Wilson M.R. The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin Biochemistry 44 2005 10914 10925 (Pubitemid 41153652)
52. French K., Yerbury J.J., and Wilson M.R. Protease activation of alpha2-macroglobulin modulates a chaperone-like broad specificity Biochemistry 47 2008 1176 1185 (Pubitemid 351161874)
53. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., and Dobson C.M. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with pre-fibrillar structures FASEB J. 21 2007 2312 2322 (Pubitemid 47230661)
54. Yerbury J.J., Kumita J.R., Meehan S., Dobson C.M., and Wilson M.R. Alpha-2-macroglobulin and haptoglobin supress amyloid formation by interacting with prefibrillar protien species J. Biol. Chem. 284 2009 4246 4252
55. Naiki H., Gejyo F., and Nakakuk K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro Biochemistry 36 1997 6243 6250 (Pubitemid 27257893)
56. Janciauskiene S., García de Frutos P., Carlemalm E., Dahlbäck B., and Eriksson S. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component J. Biol. Chem. 270 1995 26041 26044 (Pubitemid 3006164)
57. Kapron J.T., Hilliard G.M., Lakins J.N., Tenniswood M.P., West K.A., and Carr S.A. Identification and characterization of glycosylation sites in human serum clusterin Protein Sci. 6 1997 2120 2133 (Pubitemid 27449292)
58. de Silva H.V., Harmony J.A.K., Stuart W.D., Gil C.M., and Robbins J. Apolipoprotein J: structure and tissue distribution Biochemistry 29 1990 5380 5389 (Pubitemid 20193947)
59. Bailey R.W., Dunker A.K., Brown C.J., Garner E.C., and Griswold M.D. Clusterin, a binding protein with a molten globule-like region Biochemistry 40 2001 11828 11840 (Pubitemid 32906044)
60. Murphy B.F., Kriszbaum L., Walker I.D., and d'Apice J.F. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis J. Clin. Invest. 81 1988 1858 1864
61. Choi N.H., Tobe T., Hara K., Yoshida H., and Tomita M. Sandwich ELISA for quantitative measurement of SP40, 40 in seminal plasma and serum J. Immunol. Med. 131 1990 159 163 (Pubitemid 20241515)
62. Fritz I.B., Burdzy K., Setchell B., and Blaschuk O. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro Biol. Reprod. 28 1983 1173 1188 (Pubitemid 13037974)
63. Jenne D.E., and Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein Trends Biochem. Sci. 17 1992 154 159
64. Buttyan R., Olsson C.A., Pintar J., Chang C.S., Bandyk M., and Ng P.Y. Induction of the Trpm-2 gene in cells undergoing programmed cell death Mol. Cell. Biol. 9 1989 3473 3481 (Pubitemid 19189636)
65. Trougakos I.P., and Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer Int. J. Biochem. Cell Biol. 34 2002 1430 1448 (Pubitemid 35245400)
66. Strocchi P., Smith M.A., Perry G., Tamagno E., Danni O., and Pession A. Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells Neurobiol. Aging 27 2006 1588 1594 (Pubitemid 44344841)
67. Ubrich C., Fritzenwanger M., Zeiher A.M., and Dimmeler S. Laminar shear stress upregulates the complement-inhibitory protein clusterin Circulation 101 2000 352 355
68. Loison F., Debure L., Nizard P., Le Goff P., Michel D., and Le Drean Y. Up-regulation of the clusterin gene after proteotoxic stress: implications of HSF1-HSF2 heterocomplexes Biochem. J. 395 2006 223 231
69. Michel D., Chatelain G., North S., and Brun G. Stress-induced transcription of the clusterin/apoJ gene Biochem. J. 328 1997 45 50 (Pubitemid 27499438)
70. Criswell T., Beman M., Araki S., Leskov K., Cataldo E., and Mayo L.D. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor J. Biol. Chem. 280 2005 14212 14221 (Pubitemid 40517323)
71. Trougakos I.P., Pawelec G., Tzavelas C., Ntouroupi T., and Gonos E.S. Clusterin/apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells Biogerontology 7 2006 375 382
72. Silkensen J.R., Schwochau G.B., and Rosenberg M.E. The role of clusterin in tissue injury Biochem. Cell Biol. 72 1994 483 488
73. Rosenberg M.E., and Silkensen J. Clusterin: physiologic and pathophysiologic considerations Int. J. Biochem. Cell Biol. 27 1995 633 645
74. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., and Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat Neuron 5 1990 831 839
75. Nilselid A.M., Davidsson P., Nagga K., Andreasen N., Fredman P., and Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms Neurochem. Int. 48 2006 718 728
76. Shapiro L.A., Marks A., and Whitaker-Azmitia P.M. Increased clusterin expression in old but not young adult S100B transgenic mice: evidence of neuropathological aging in a model of Down Syndrome Brain Res. 1010 2004 17 21 (Pubitemid 38569848)
77. Kim B.M., Han Y.M., Shin Y.J., Min B.H., and Park I.S. Clusterin expression during regeneration of pancreatic islet cells in streptozotocin- induced diabetic rats Diabetologia 44 2001 2192 2202
78. Trougakos I.P., Poulakou M., Stathatos M., Chalikia A., Melidonis A., and Gonos E.S. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction Exp. Gerontol. 37 2002 1175 1187 (Pubitemid 35418275)
79. Morgan T.E., Xie Z., Goldsmith S., Yoshida T., Lanzrein A.S., and Stone D. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction Neuroscience 89 1999 687 699 (Pubitemid 29070996)
80. Poon S., Rybchyn M.S., Easterbrook-Smith S.B., Carver J.A., and Wilson M.R. Clusterin is an ATP-independent chaperone with a very broad substrate specificity that stabilizes stressed proteins in a folding-competent state Biochemistry 39 2000 15953 15960 (Pubitemid 32038257)
81. Wyatt A.R., Yerbury J.J., and Wilson M.R. Structural characterization of clusterin-client protein complexes J. Biol. Chem. 284 2009 21920 21927
82. Poon S., Rybchyn M.S., Easterbrook-Smith S.B., Carver J.A., Pankhurst G.J., and Wilson M.R. Mildly acidic pH activates the extracellular molecular chaperone clusterin J. Biol. Chem. 277 2002 39532 39540 (Pubitemid 35190931)
83. Wyatt A.R., and Wilson M.R. Identification of human plasma proteins as major clients for the extracellular chaperone clusterin J. Biol. Chem. 285 2010 3532 3539
84. Kumita J.R., Poon S., Caddy G.L., Hagan C.L., Dumoulin M., and Yerbury J.J. The extracellular chaperone clusterin potentially inhibits amyloid formation by interacting with prefibrillar species J. Mol. Biol. 369 2007 157 167 (Pubitemid 46635433)
85. Hatters D.M., Wilson M.R., Easterbrook-Smith S.B., and Howlett G.J. Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin Eur. J. Biochem. 269 2002 2789 2794 (Pubitemid 34595647)
86. McHattie S., and Edington N. Clusterin prevents aggregation of neuropeptide 106-126 in vitro Biochem. Biophys. Res. Commun. 259 1999 336 340 (Pubitemid 29281232)
87. Matsubara E., Frangione B., and Ghiso J. Characterization of apolipoprotein J-Alzheimer's a-beta interaction J. Biol. Chem. 270 1995 7563 7567
88. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., and Morgan T.E. Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress Exp. Neurol. 136 1995 22 31
89. Boggs L.N., Fuson K.S., Baez M., Churgay L., McClure D., and Becker G. Clusterin (Apo J) protects against in vitro amyloid-β(1-40) neurotoxicity J. Neurochem. 67 1996 1324 1327 (Pubitemid 26277948)
90. Bailey R.W., Aronow B., Harmony J.A.K., and Griswold M.D. Heat shock-initiated apoptosis is accelerated and removal of damaged cells is delayed in the testis of clusterin/apoJ knock-out mice Biol. Reprod. 66 2002 1042 1053 (Pubitemid 34263124)
91. McLaughlin L., Zhu G., Mistry M., Ley-Ebert C., Stuart W.D., and Florio C.J. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis J. Clin. Invest. 106 2000 1105 1113
92. Wehrli P., Charnay Y., Vallet P., Zhu G., Harmony J., and Aronow B. Inhibition of post-ischemic brain injury by clusterin overexpression Nat. Med. 7 2001 977 978
93. Rosenberg M.E., Girton R., Finkel D., Chmielewski D., Barrie A., and Witte D.P. Apolipoprotein J/clusterin prevents progressive glomerulopathy of aging Mol. Cell. Biol. 22 2002 1893 1902 (Pubitemid 34175004)
94. DeMattos R.D., O'dell M.A., Parsadanian M., Taylor J.W., Harmony J.A.K., and Bales K.R. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease Proc. Natl Acad. Sci. USA 99 2002 10843 11084
95. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., and Taylor J.W. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in vivo Neuron 41 2004 193 202 (Pubitemid 38125181)
96. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., and Deane R. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system J. Cereb. Blood Flow. Metab. 27 2007 909 918 (Pubitemid 46659038)
97. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., and Small G.W. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923 (Pubitemid 23275809)
98. Raber J., Huang Y., and Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology Neurobiol. Aging 25 2004 641 650 (Pubitemid 38686487)
99. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., and Hamshere M.L. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat. Genet. 41 2009 1088 1093
100. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., and Hiltunen M. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat. Genet. 41 2009 1094 1099
101. Bowman B.H., and Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation Adv. Hum. Genet. 12 1982 189 261
102. Kurosky A., Barnett D.R., Lee T.H., Touchstone B., Hay R.E., and Arnott M.S. Covalent structure of human haptoglobin: a serine protease homolog Proc. Natl Acad. Sci. USA 77 1980 3388 3392 (Pubitemid 10012242)
103. Polticelli F., Bocedi A., Minervini G., and Ascenzi P. Human haptoglobin structure and function - a molecular modelling study FEBS J. 275 2008 5648 5656
104. Ettrich R., Brandt W., Kopecky V., Baumruk V., Hofbauerova K., and Pavlicek Z. Study of chaperone-like activity of human haptoglobin: conformational changes under heat shock conditions and localization of interaction sites Biol. Chem. 383 2002 1667 1676 (Pubitemid 35282986)
105. Sobek O., and Adam P. On S. Seygert, V. Kunzmann, N. Schwertfeger, H. C. Koch, A. Faulstich: determinants of lumbar CSF protein concentration J. Neurol. 250 2003 371 372 (Pubitemid 36399285)
106. Louagie H., Delanghe J., Desombere I., De Buyzere M., Hauser P., and Leroux-Roels G. Haptoglobin polymorphism and the immune response after hepatitis B vaccination Vaccine 11 1993 1188 1190 (Pubitemid 23308774)
107. Oh S.K., Pavlotsky N., and Tauber A.I. Specific binding of haptoglobin to human neutrophils and its functional consequences J. Leukoc. Biol. 47 1990 142 148 (Pubitemid 20061667)
108. Snellman O., and Sylven B. Haptoglobin acting as a natural inhibitor of cathepsin B activity Nature 216 1967 1033
109. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., and Kleinman H.K. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis J. Clin. Invest. 91 1993 977 985 (Pubitemid 23095272)
110. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphisms in humans Clin. Chem. 42 1996 1589 1600 (Pubitemid 26354735)
111. Gutteridge J.M. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation Biochim. Biophys. Acta 917 1987 219 223 (Pubitemid 17004970)
112. Edwards D.H., Griffith T.M., Ryley H.C., and Henderson A.H. Haptoglobin-haemoglobin complex in human plasma inhibits endothelium dependent relaxation: evidence that endothelium derived relaxing factor acts as a local autocoid Cardiovasc. Res. 20 1986 549 556 (Pubitemid 16053576)
113. Lange V. Haptoglobin polymorphisms - not only a genetic marker Anthropol. Anz. 50 1992 281 302
114. Levy A.P., Hochberg I., Jablonski K., Resnick H.E., Lee E.T., and Best L. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study J. Am. Coll. Cardiol. 40 2002 1984 1990 (Pubitemid 35425366)
115. Shor M., Boaz M., Gavish D., Wainshtein J., Matas Z., and Shargorodsky M. Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus Am. J. Cardiol. 100 2007 1767 1770 (Pubitemid 350234796)
116. Jung S.M., Lee K., Lee J.W., Namkoong H., Kim H.K., and Kim S. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease Neurosci. Lett. 436 2008 153 157
117. Roher A.E., Maarouf C.L., Sue L.I., Hu Y., Wilson J., and Beach T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease Biomarkers 14 2009 493 501
118. Teunissen C.E., van Boxtel M.P., Bosma H., Bosmans E., Delanghe J., and De Bruijn C. Inflammation markers in relation to cognition in a healthy aging population J. Neuroimmunol. 134 2003 142 150 (Pubitemid 36054172)
119. Taira T., Fujinaga T., Okumura M., Yamashita K., Tsunoda N., and Mizuno S. Equine haptoglobin: isolation, characterization, and the effects of ageing, delivery and inflammation on its serum concentration J. Vet. Med. Sci. 54 1992 435 442
120. Pavlicek Z., and Ettrich R. Chaperone-like activity of human haptoglobin: Similarity with alpha-crystallin Collect. Czech. Chem. Commun. 64 1999 717 725
121. de Albuquerque Wobeto V.P., Zaccariotto T.R., and de Fátima Sonat M. Polymorphism of human haptoglobin and its clinical importance Genet. Mol. Biol. 31 2008 602 620
122. Graversen J.H., Madsen M., and Moestrup S.K. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma Int. J. Biochem. Cell Biol. 34 2002 309 314 (Pubitemid 34164272)
123. Ross G.D. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein Crit. Rev. Immunol. 20 2000 197 222 (Pubitemid 30645020)
124. Jensen P.E., and Sottrup-Jensen L. Primary structure of human alpha 2-macroglobulin. Complete disulfide bridge assignment and localization of two interchain bridges in the dimeric proteinase binding unit J. Biol. Chem. 261 1986 15863 15869 (Pubitemid 17202827)
125. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., and Fairbrother W.J. Structure of C3b in complex with CRIg gives insights into regulation of complement activation Nature 444 2006 217 220 (Pubitemid 44722063)
126. Abdul Ajees A., Gunasekaran K., Volanakis J.E., Narayana S.V., Kotwal G.J., and Murthy H.M. The structure of complement C3b provides insights into complement activation and regulation Nature 444 2006 221 225 (Pubitemid 44780686)
127. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., and Nilsson-Ekdahl K. Structures of complement component C3 provide insights into the function and evolution of immunity Nature 437 2005 505 511 (Pubitemid 41613542)
128. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., and Gros P. Structure of C3b reveals conformational changes that underlie complement activity Nature 444 2006 213 216 (Pubitemid 44722062)
129. Doan N., and Gettins P.G. Human alpha2-macroglobulin is composed of multiple domains, as predicted by homology with complement component C3 Biochem. J. 407 2007 23 30 (Pubitemid 47535577)
130. Biringer R.G., Amato H., Harrington M.G., Fonteh A.N., Riggins J.N., and Huhmer A.F. Enhanced sequence coverage of proteins in human cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LC-MS/MS Brief. Funct. Genomics Proteomics 5 2006 144 153 (Pubitemid 46403007)
131. Sottrup-Jensen L. Alpha-macroglobulins: structure shape and mechanism of proteinase complex formation J. Biol. Chem. 264 1989 11539 11542 (Pubitemid 19185316)
132. Borth W. Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics FASEB J. 6 1992 3345 3353 (Pubitemid 23007099)
133. Armstrong P.B., and Quigley J.P. Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system Dev. Comp. Immunol. 23 1999 375 390 (Pubitemid 29309614)
134. Chu C.T., and Pizzo S.V. Receptor-mediated antigen delivery into macrophages. Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells J. Immunol. 150 1993 48 58 (Pubitemid 23069779)
135. Binder R.J., Karimeddini D., and Srivastava P.K. Adjuvanticity of alpha2-macroglobulin, an independent ligand for the heat shock protein receptor CD91 J. Immunol. 166 2001 4968 4972 (Pubitemid 32280707)
136. Misra U.K., Deedwania R., and Pizzo S.V. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78 J. Biol. Chem. 281 2006 13694 13707 (Pubitemid 43855285)
137. Narita M., Holtzman D.M., Schwartz A.L., and Bu G. α2-macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein J. Neurochem. 69 1997 1904 1911 (Pubitemid 27452736)
138. Du Y., Bales K.R., Dodel R.C., Liu X., Glinn M.A., and Horn J.W. α2-Macroglobulin attenuates β-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons J. Neurochem. 70 1998 1182 1188 (Pubitemid 28113653)
139. Poduslo S.E., and Yin X. Chromosome 12 and late-onset Alzheimer's disease Neurosci. Lett. 310 2001 188 190 (Pubitemid 32822834)
140. Rogaeva E.A., Premkumar S., Grubber J., Serneels L., Scott W.K., and Kawarai T. An alpha2-macroglobulin insertion-deletion polymorphism in Alzheimer disease Nat. Genet. 22 1999 19 21
141. Saunders A.J., Bertram L., Mullin K., Sampson A.J., Latifzai K., and Basu S. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin Hum. Mol. Genet. 12 2003 2765 2776 (Pubitemid 37407113)
142. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., and Go R.C.P. Alpha-2 macroglobulin is genetically associated with Alzheimer disease Nat. Genet. 19 1998 357 360 (Pubitemid 28357907)
143. Bruno E., Quattrocchi G., Nicoletti A., Le Pira F., Maci T., and Mostile G. Lack of interaction between LRP1 and A2M polymorphisms for the risk of Alzheimer disease Neurosci. Lett. 482 2010 112 116
144. Jhoo J.H., Kim K.W., Lee D.Y., Lee K.U., Lee J.H., and Kim S.Y. Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans J. Neurol. Sci. 184 2001 21 25 (Pubitemid 32166721)
145. Flachsbart F., Caliebe A., Nothnagel M., Kleindorp R., Nikolaus S., and Schreiber S. Depletion of potential A2M risk haplotype for Alzheimer's disease in long-lived individuals Eur. J. Hum. Genet. 18 2010 59 61
146. Wang X., Luedecking E.K., Minster R.L., Ganguli M., DeKosky S.T., and Kamboh M.I. Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer's disease Hum. Genet. 108 2001 105 108 (Pubitemid 32215368)
147. Hollenbach E., Ackermann S., Hyman B.T., and Rebeck G.W. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease Neurology 50 1998 1905 1907 (Pubitemid 28283283)
148. Kang D.E., Saitoh T., Chen X., Xia Y., Masliah E., and Hansen L.A. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease Neurology 49 1997 56 61 (Pubitemid 27328682)
149. Coker A.R., Purvis A., Baker D., Pepys M.B., and Wood S.P. Molecular chaperone properties of serum amyloid P component FEBS Lett. 463 2000 199 202 (Pubitemid 30254290)
150. Tennent G.A., Lovat L.B., and Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis Proc. Natl Acad. Sci. USA 92 1995 4299 4303
151. Breathnach S.M., Bhogal B., Dyck R.F., De Beer F.C., Black M.M., and Pepys M.B. Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis Br. J. Dermatol. 105 1981 115 124 (Pubitemid 11051283)
152. Coria F., Castano E., Prelli F., Larrondo-Lillo M., van Duinen S., and Shelanski M.L. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis Lab. Invest. 58 1988 454 458
153. Kalaria R.N., Galloway P.G., and Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders Neuropathol. Appl. Neurobiol. 17 1991 189 201
154. Yang G.C., Nieto R., Stachura I., and Gallo G.R. Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy Am. J. Pathol. 141 1992 409 419
155. Botto M., Hawkins P.N., Bickerstaff M.C.M., Herbert J., Bygrave A.E., and McBride A. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene Nat. Med. 3 1997 855 859 (Pubitemid 27353444)
156. Evans K.C., Berger E.P., Cho C.G., Weisgraber K.H., and Lansbury P.T. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease Proc. Natl Acad. Sci. USA 92 1995 763 767
157. EC, the C-terminal extension of fibrinogen, has chaperone-like activity Biochemistry 48 2009 3967 3976
158. Koldamova R.P., Lefterov I.M., Lefterova M.I., and Lazo J.S. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits Aβ aggregation and toxicity Biochemistry 40 2001 3553 3560 (Pubitemid 32242812)
159. Jarabak R., Westley J., Dungan J.M., and Horowitz P. A chaperone-mimetic effect of serum albumin on rhodanese J. Biochem. Toxicol. 8 1993 41 48
160. Marini I., Moschini R., Del Corso A., and Mur U. Chaperone-like features of bovine serum albumin: a comparison with a-crystallin Cell. Mol. Life Sci. 62 2005 3092 3099 (Pubitemid 43004757)
161. Bohrmann B., Tjernberg L., Kuner P., Poli S., Levet-Trafit B., and Näslund J. Endogenous proteins controlling amyloid β-peptide polymerization J. Biol. Chem. 274 1999 115990 115995
162. Treweek T.M., Thorn D.C., Price W.E., and Carver J.A. The chaperone action of bovine milk αS1- and αS2-caseins and their associated form αS-casein Arch. Biochem. Biophys. 510 2011 42 52
163. Morgan P.E., Treweek T.M., Linder R.A., Price W.E., and Carver J.A. Casein proteins as molecular chaperones J. Agric. Food Chem. 53 2005 2670 2683 (Pubitemid 40471750)
164. Thorn D.C., Ecroyd H., and Carver J.A. The two-faced nature of milk casein proteins: amyloid fibril formation and chaperone-like activity Aust. J. Dairy Technol. 64 2009 36 40
165. Bhattacharyya J., and Das K.P. Molecular chaperone-like properties of an unfolded protein, alpha(s)-casein J. Biol. Chem. 274 1999 15505 15509
166. Reid I.M. Corpora amylacea of the bovine mammary gland. Histochemical and electron microscopic evidence for their amyloid nature J. Comp. Pathol. 82 1972 409 413
167. Taniyama H., Kitamura A., Kagawa Y., Hirayama K., Yoshino T., and Kamiya S. Localized amyloidosis in canine mammary tumors Vet. Pathol. 37 2000 104 107
168. Nickerson S.C. Amyloid fibril formation in the bovine mammary gland: an ultrastructural study Cytobios 51 1987 81 92
169. Emerson R.O., Sage E.H., Ghosh J.G., and Clark J.I. Chaperone-like activity revealed in the matricellular protein SPARC J. Cell. Biochem. 98 2006 701 705 (Pubitemid 43993388)
170. Gilmour D.T., Lyon G.J., Carlton M.B., Sanes J.R., Cunningham J.M., and Anderson J.R. Mice deficient for the secreted glycoprotein SPARC/osteonectin/ BM40 develop normally but show severe age-onset cataract formation and disruption of the lens EMBO J. 17 1998 1860 1870 (Pubitemid 28154517)
171. Norose K., Clark J.I., Syed N.A., Basu A., Heber-Katz E., and Sage E.H. SPARC deficiency leads to early-onset cataractogenesis Invest. Ophthalmol. Vis. Sci. 39 1998 2674 2680 (Pubitemid 28558226)
172. Cherepkova O.A., Lyutova E.M., Eronina T.B., and Gurvits B.Y. Chaperone-like activity of macrophage migration inhibitory factor Int. J. Biochem. Cell Biol. 38 2006 43 55 (Pubitemid 41540716)
173. Oyama R., Yamamotoc H., and Titani K. Glutamine synthetase, hemoglobin α-chain, and macrophage migration inhibitory factor binding to amyloid β-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation Biochim. Biophys. Acta 1479 2000 91 102 (Pubitemid 30345627)
174. Bharadwaj D., Mold C., Markham E., and Du Clos T.W. Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis J. Immunol. 166 2001 6735 6741 (Pubitemid 32467217)
175. Carlsson J., Armstrong V.W., Reiber H., Felgenhaur K., and Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid Clin. Chim. Acta 196 1991 167 176
176. G. Siest, A. Schlenck, M. Starck, M. Vincent-Viry, F. Schiele, and S. Visvikis Apolipoprotein E: Laboratory Determinations and Clinical Interest 2000 AACC Press Washington, DC 401 441
177. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., and Salvesen G.S. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc. Natl Acad. Sci. USA 90 1993 1977 1981 (Pubitemid 23069980)
178. Baumann M.H., Kallijärvi J., Lankinen H., Soto C., and Haltia M. Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides Biochem. J. 349 2000 77 84 (Pubitemid 30440167)
179. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., and Patterson B.W. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance Sci. Transl. Med. 3 2011 89ra57
180. Segrest J.P., Jones M.K., De Loof H., Brouillette C.G., Venkatachalapathi Y.V., and Anantharamaiah G.M. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function J. Lipid Res. 33 1992 141 166
181. Tang H., Fu Y., Cui Y., He Y., Zeng X., and Ploplis V.A. Fibrinogen has chaperone-like activity Biochem. Biophys. Res. Commun. 378 2009 662 667
182. Grieninger G., Lu X., Cao Y., Fu Y., Kudryk B.J., and Galanakis D.K. Fib420, the novel fibrinogen subclass: newborn levels are higher than adult Blood 90 1997 2609 2614 (Pubitemid 27413470)
183. Biere A.L., Ostaszewski B., Stimson E.R., Hyman B.T., Maggio J.E., and Selkoe D.J. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma J. Biol. Chem. 271 1996 32916 32922 (Pubitemid 27008725)
184. Morgan C., Colombres M., Nunez M.T., and Inestrosa N.C. Structure and function of amyloid in Alzheimer's disease Prog. Neurobiol. 74 2004 323 349 (Pubitemid 40092735)
185. Reyes Barcelo A.A., Gonzalez-Velasquez F.J., and Moss M.A. Soluble aggregates of the amyloid-β peptide are trapped by serum albumin to enhance amyloid-β activation of endothelial cells J. Biol. Eng. 3 2009 5
186. Horowitz J. a-Crystallin can function as a molecular chaperone Proc. Natl Acad. Sci. USA 89 1992 10449 10453
187. Muchowski P.J., and Clark J.I. ATP-enhanced molecular chaperone functions of the small heat shock protein human αB crystallin Proc. Natl Acad. Sci. USA 95 1998 1004 1009 (Pubitemid 28124902)
188. Chlenski A., Guerrero L.J., Salwen H.R., Yang Q., Tian Y., and Morales La Madrid A. Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone PLoS One 6 2011 e23880
189. Martinek N., Shahab J., Sodek J., and Ringuette M. Is SPARC an evolutionarily conserved collagen chaperone? J. Dent. Res. 86 2007 296 305
190. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356 (Pubitemid 34790756)
191. Scheuner D., Eckman C., Jensen M., Song X., Citron M., and Suzuki N. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease Nat. Med. 2 1996 864 870 (Pubitemid 26296755)
192. Mangialasche F., Solomon A., Winblad B., Mecocci P., and Kivipelto M. Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 2010 702 716
193. Falk R., Maurer M., Fedson S., Judge D., Zeldenrust S., and Quyyumi A. Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy J. Card. Failure 17 2011 S56
194. Jin M., Shepardson N., Yang T., Chen G., Walsh D., and Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proc. Natl Acad. Sci. USA 108 2011 5819 5824
195. Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., and Crowther D.C. ANS binding reveals common features of cytotoxic amyloid species ACS Chem. Biol. 5 2010 735 740
196. Su Y., and Chang P.T. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide Brain Res. 893 2001 287 291 (Pubitemid 32171924)
197. Wolfe M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease Neurotherapeutics 5 2008 391 398 (Pubitemid 351952492)
198. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., and Bara T. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J. Biol. Chem. 279 2004 12876 12882 (Pubitemid 38445862)
199. Savonenko A.V., Melnikova T., Hiatt A., Li T., Worley P.F., and Troncoso J.C. Alzheimer's therapeutics: translation of preclinical science to clinical drug development Neuropsychopharmacology 37 2012 261 277
200. Gauthier S., Aisen P.S., Ferris S.H., Saumer D., Duong A., and Haine D. Effect of tramiposate in patients with mild-to-moderate alzheimer's disease: exploratory analyses of the MRI sub-group of the alphase study J. Nutr. Health Aging 13 2009 550 557
201. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., and Phinney A.L. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model Nat. Med. 12 2006 801 808 (Pubitemid 44050070)
202. Salloway S., Sperling R., Keren R., Porsteinsson A.P., van Dyck C.H., and Tariot P.N. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease Neurology 77 2011 1253 1262
203. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., and Morris J.C. Decreased clearance of CNS beta-amyloid in Alzheimer's disease Science 330 2010 1774
204. Wilson M.R., Yerbury J.J., and Poon S. Extracellular chaperones and amyloids A. Asea, I. Brown, Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection 2008 Springer Science 283 315
205. Eikelenboom P., Veerhuis R., van Exel E., Hoozemans J.J., Rozemuller A.J., and van Gool W.A. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence Curr. Alzheimer Res. 8 2011 142 150
206. Gebbink M.F. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis J. Thromb. Haemost. 9 2011 174 181
207. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.H., Tomita M., and Wisniewski T. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex Biochem. J. 293 1993 27 30 (Pubitemid 23223142)
208. Du Y., Ni B., Glinn M., Dodel R.C., Bales K.R., and Zhang Z. Alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein J. Neurochem. 69 1997 299 305 (Pubitemid 27274185)
209. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., and Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide J. Biol. Chem. 272 1997 18644 18649 (Pubitemid 27318206)
210. Urmoneit B., Prikulis I., Wihl G., D'Urso D., Frank R., and Heeren J. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy Lab. Invest. 77 1997 157 166 (Pubitemid 27355912)
211. Yerbury J.J., and Wilson M.R. Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Ab toxicity and uptake Cell Stress Chaperones 15 2010 115 121
212. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., and Frangione B. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier J. Clin. Invest. 106 2000 1489 1499 (Pubitemid 32038587)
213. Bertram L., K. Mullin, D. Blacker, and R. Tanzi The AlzGene Database 2011 Alzheimer Research Forum Available at http://www.alzgene.org
214. Floege J., Bartsch A., Schulze M., Shaldon S., Koch K.M., and Smeby L.C. Clearance and synthesis rates of beta 2-microglobulin in patients undergoing hemodialysis and in normal subjects J. Lab. Clin. Med. 118 1991 153 165
215. Longo Alves I., Hays M.T., and Saraiva M.J. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin Eur. J. Biochem. 249 1997 662 668 (Pubitemid 27479035)
216. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., and Gillmore J.D. Natural history and outcome in systemic AA amyloidosis N. Engl. J. Med. 356 2007 2367 2371
217. Kazama J.J., Maruyama H., and Gejyo F. Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis Nephrol. Dial. Transplant. 16 2011 31 35
218. Lachmann H.J., Gallimore R., Gillmore J.D., Carr-Smith H.D., Bradwell A.R., and Pepys M.B. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Br. J. Haematol. 122 2003 78 84 (Pubitemid 36819341)